

10/590427
1AP9 Rec'd PCT/PTO 23 AUG 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Weggeman et al.

Serial No.: To be assigned

Filed: August 23, 2006

For: VIRUS PURIFICATION METHODS

Confirmation No.: To be assigned

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2578-7869US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV826301234US

Date of Deposit with USPS: August 23, 2006

Person making Deposit: Brett Hooke

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

10/590427

AP9 Rec'd PCT/PTO 23 AUG 2006

Attorney Docket No.: 2578-7869US

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 5,559,099	09-24-1996	Wickham et al.
US - 5,789,390	08-04-1998	Descamps et al.
US - 5,837,511	11-17-1998	Falck-Pedersen et al.
US - 5,837,520	11-17-1998	Shabram et al.
US - 5,840,565	11-24-1998	Lau
US - 5,846,782	12-08-1998	Wickham et al.
US - 5,851,806	12-22-1998	Kovesdi et al.
US - 5,891,690	04-06-1999	Massie
US - 5,948,410	09-07-1999	Van Scharrenburg et al.
US - 5,965,541	10-12-1999	Wickham et al.
US - 5,981,225	11-09-1999	Kochanek et al.
US - 5,994,106	11-30-1999	Kovesdi et al.
US - 5,994,128	11-30-1999	Fallaux et al.
US - 5,994,134	11-30-1999	Giroux et al.
US - 6,008,036	12-28-1999	Fanget et al.
US - 6,020,191	02-01-2000	Scaria et al.
US - 6,040,174	03-21-2000	Imler et al.
US - 6,113,913	09-05-2000	Brough et al.
US - 6,146,873	11-14-2000	Kistner et al.
US - 6,168,941	01-02-2001	Liu et al.
US - 6,168,944	01-02-2001	Condon et al.
US - 6,261,823	07-17-2001	Tang et al.
US - 6,309,650	10-30-2001	Kim et al.
US - 6,342,384	01-29-2002	Chung et al.
US - 6,485,958	11-26-2002	Blanche et al.
US - 6,492,169	12-10-2002	Vogels et al.
US - 6,537,793	03-25-2003	Blanche et al.

Attorney Docket No.: 2578-7869US

US - 6,586,226	07-01-2003	Carrion et al.
US - 2002/182723	12-05-2002	Toohyon et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
EP 1 230 354 B1	08-14-2002	Cevec Pharmaceuticals GmbH
WO 99/41416	08-19-1999	Schering Corp.
WO 99/12568	03-18-1999	Merck & Co., Inc.
WO 98/39411	09-11-1998	Baxter Int'l, Inc.
WO 98/22588	05-28-1998	Introgen Therapeutics, Inc.
WO 97/08298	03-06-1997	Genzyme Corp.
WO 96/26281	08-29-1996	Genvec, Inc. et al.
WO 03/084479	10-16-2003	Merck & Co., Inc.
WO 03/097797	11-27-2003	Merck & Co., Inc.
WO 03/104467	12-18-2003	Crucell Holland B.V.
WO 2004/001032	12-31-2003	Crucell Holland B.V.
WO 03/078592	09-25-2003	Cell Genesys, Inc.
WO 03/028632	04-10-2003	Government of the U.S.A., as represented by the Secretary, Dept. of H. H. S.
WO 03/049763	06-19-2003	Mayne Pharma PTY LTD
WO 02/070673	09-12-2002	Schering Aktiengesellschaft
WO 02/44348	06-06-2002	Schering Corp.
WO 01/77304	10-18-2001	Genvec, Inc.
WO 02/22080	03-21-2002	Merck & Co., Inc.
WO 00/50573	08-31-2000	Transgene S.A.
WO 00/03029	01-20-2000	Introgene B.V.
WO 2005/080556	09-01-2005	Crucell Holland B.V.
WO 00/70071	11-23-2000	Introgene B.V.

Attorney Docket No.: 2578-7869US

WO 01/38362

05-31-2001

Crucell Holland B.V.

Other Documents

PCT International Preliminary Report on Patentability, PCT/ EP2005/050439,
dated July 18, 2006.

PCT International Search Report, PCT/EP 2005/050439, dated October 27, 2005.

GREEN et al., "A new Scalable Method for the Purification of Recombinant
Adenovirus Vectors," Human Gene Therapy, 1 November 2002, pp. 1921-1934, Vol. 13.

DRITTANTI et al., "Optimised helper virus-free production of high-quality
adeno-associated virus vectors," The Journal of Gene Medicine, 2001, pp. 59-71, Vol. 3.

SULLIVAN et al., "Development of a preventive vaccine for Ebola virus infection
in primates," Nature, 30 November 2000, pp. 609-609, Vol. 408.

This Information Disclosure Statement is filed within three (3) months of the filing date
of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee
pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Kelly A. Echols
Registration No. 55,911
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: August 23, 2006
KAE/alb

Enclosures: Form PTO/SB/08
Cited Non-U.S. Patent Documents
Document in ProLaw

10/590427
1AP9 Rec'd PCT/PTO 23 AUG 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet 1 of 3

Application Number	To be assigned
Filing Date	August 23, 2006
First Named Inventor	Weggeman et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2578-7869US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,559,099	09-24-1996	Wickham et al.	
		US- 5,789,390	08-04-1998	Descamps et al.	
		US- 5,837,511	11-17-1998	Falck-Pedersen et al.	
		US- 5,837,520	11-17-1998	Shabram et al.	
		US- 5,840,565	11-24-1998	Lau	
		US- 5,846,782	12-08-1998	Wickham et al.	
		US- 5,851,806	12-22-1998	Kovesdi et al.	
		US- 5,891,690	04-06-1999	Massie	
		US- 5,948,410	09-07-1999	Van Scharrenburg et al.	
		US- 5,965,541	10-12-1999	Wickham et al.	
		US- 5,981,225	11-09-1999	Kochanek et al.	
		US- 5,994,106	11-30-1999	Kovesdi et al.	
		US- 5,994,128	11-30-1999	Fallaux et al.	
		US- 5,994,134	11-30-1999	Giroux et al.	
		US- 6,008,036	12-28-1999	Fanget et al.	
		US- 6,020,191	02-01-2000	Scaria et al.	
		US- 6,040,174	03-21-2000	Imler et al.	
		US- 6,113,913	09-05-2000	Brough et al.	
		US- 6,146,873	11-14-2000	Kistner et al.	
		US- 6,168,941	01-02-2001	Liu et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		EP 1 230 354 B1	08-14-2002	Cevec Pharmaceuticals GmbH		
		WO 99/41416	08-19-1999	Schering Corp.		
		WO 99/12568	03-18-1999	Merck & Co., Inc.		
		WO 98/39411	09-11-1998	Baxter Int'l, Inc.		
		WO 98/22588	05-28-1998	Introgen Therapeutics, Inc.		
		WO 97/08298	03-06-1997	Genzyme Corp.		
		WO 96/26281	08-29-1996	Genvec, Inc. et al.		
		WO 03/084479	10-16-2003	Merck & Co., Inc.		
		WO 03/097797	11-27-2003	Merck & Co., Inc.		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

10/590427
IAP9 Rec'd PGT/PTO 23 AUG 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number

To be assigned

Filing Date

August 23, 2006

First Named Inventor

Weggeman et al.

Group Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

2578-7869US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US - 6,168,944	01-02-2001	Condon et al.	
		US - 6,261,823	07-17-2001	Tang et al.	
		US - 6,309,650	10-30-2001	Kim et al.	
		US - 6,342,384	01-29-2002	Chung et al.	
		US - 6,485,958	11-26-2002	Blanche et al.	
		US - 6,492,169	12-10-2002	Vogels et al.	
		US - 6,537,793	03-25-2003	Blanche et al.	
		US - 6,586,226	07-01-2003	Carrión et al.	
		US - 2002/182723	12-05-2002	Toohyon et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 03/104467	12-18-2003	Crucell Holland B.V.		
		WO 2004/001032	12-31-2003	Crucell Holland B.V.		
		WO 03/078592	09-25-2003	Cell Genesys, Inc.		
		WO 03/028632	04-10-2003	Government of the U.S.A., as represented by the Secretary, Dept. of H. H. S.		
		WO 03/049763	06-19-2003	Mayne Pharma PTY LTD		
		WO 02/070673	09-12-2002	Schering Aktiengesellschaft		
		WO 02/44348	06-06-2002	Schering Corp.		
		WO 01/77304	10-18-2001	Genvec, Inc.		
		WO 02/22080	03-21-2002	Merck & Co., Inc.		
		WO 00/50573	08-31-2000	Transgene S.A.		
		WO 00/03029	01-20-2000	Introgene B.V.		
		WO 2005/080556	09-01-2005	Crucell Holland B.V.		
		WO 00/70071	11-23-2000	Introgene B.V.		
		WO 01/38362	05-31-2001	Crucell Holland B.V.		

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

10/590427
IAP9 Rec'd PCT/PTO 23 AUG 2006

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	To be assigned
				Filing Date	August 23, 2006
				First Named Inventor	Weggeman et al.
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	3	Attorney Docket Number	2578-7869US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Preliminary Report on Patentability, PCT/ EP2005/050439, dated July 18, 2006.	
		PCT International Search Report, PCT/EP 2005/050439, dated October 27, 2005.	
		GREEN et al., "A new Scalable Method for the Purification of Recombinant Adenovirus Vectors," Human Gene Therapy, 1 November 2002, pp. 1921-1934, Vol. 13.	
		DRITTANTI et al., "Optimised helper virus-free production of high-quality adeno-associated virus vectors," The Journal of Gene Medicine, 2001, pp. 59-71, Vol. 3.	
		SULLIVAN et al., "Development of a preventive vaccine for Ebola virus infection in primates," Nature, 30 November 2000, pp. 609-609, Vol. 408.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

+